1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18976
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBalafa, O.en
dc.contributor.authorKarabina, S. A.en
dc.contributor.authorPappas, C. A.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorSiamopoulos, K. C.en
dc.date.accessioned2015-11-24T18:56:03Z-
dc.date.available2015-11-24T18:56:03Z-
dc.identifier.issn1660-2137-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18976-
dc.rightsDefault Licence-
dc.subject1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood/chemistry/*urineen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLipoproteins/metabolism/urineen
dc.subjectLipoproteins, HDL/blood/metabolismen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNephrotic Syndrome/blood/*enzymology/*urineen
dc.titleUrine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteinsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1159/000078645-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15292677-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000078645&Ausgabe=230135&ProduktNr=228541&filename=000078645.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2004-
heal.abstractBACKGROUND: Platelet-activating factor (PAF) is a proinflammatory phospholipid mediator involved in the pathogenesis of glomerulonephritis (GN). In plasma, PAF is hydrolyzed and inactivated by PAF-acetylhydrolase (PAF-AH), an enzyme associated with lipoproteins, mainly with the low-density lipoprotein. PAF-AH activity has been found in urine of patients with primary GN, however the source and type of urinary PAF-AH remain unknown. We characterized the type of PAF-AH excreted in the urine of patients with primary GN and studied the possible relationship of this enzyme with the lipiduria and proteinuria observed in these patients. METHODS: Eighteen patients with primary GN (8 with nephrotic syndrome (NS) and 10 with non-nephrotic range proteinuria (NNRP)) and 20 normolipidemic age- and sex-matched controls participated in the study. PAF-AH activity in plasma, in urine and in individual lipoprotein particles was determined by the trichloroacetic acid precipitation procedure, whereas the PAF-AH protein was detected by Western blotting analysis. Plasma and urine lipoproteins were fractionated by gradient ultracentrifugation and characterized by Western blotting analysis. RESULTS: Plasma PAF-AH activity was higher in NS patients compared with NNRP patients and controls, whereas the enzyme activity associated with high-density lipoprotein was significantly lower in both patient groups compared with controls. PAF-AH was detected only in the urine of NS patients. It was the plasma type of PAF-AH and was associated with lipoprotein particles. Enzyme activity was also positively correlated with urine cholesterol levels. CONCLUSION: Urine of NS patients contains the plasma type of PAF-AH, which is related to the extent of lipiduria and is associated with urine lipoproteins.en
heal.journalNameNephron Physiolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Balafa-2004-Urine of patients wi.pdf229.28 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons